Search
Boston, MA Paid Clinical Trials
A listing of 2672 clinical trials in Boston, MA actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1705 - 1716 of 2672
There are currently 2672 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center and Brigham and Women's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
Recruiting
This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with congestive heart failure receiving therapy for breast cancer. Studying samples of germline DNA in the laboratory from patients with congestive heart failure receiving therapy for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to congestive heart failure.
Gender:
ALL
Ages:
All
Trial Updated:
12/24/2024
Locations: Eastern Cooperative Oncology Group, Boston, Massachusetts
Conditions: Breast Carcinoma
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer
Recruiting
This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with peripheral neuropathy receiving chemotherapy for breast cancer. Studying samples of germline DNA in the laboratory from patients with peripheral neuropathy receiving paclitaxel for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to peripheral neuropathy.
Gender:
ALL
Ages:
All
Trial Updated:
12/24/2024
Locations: Eastern Cooperative Oncology Group, Boston, Massachusetts
Conditions: Breast Carcinoma, Neuropathy
The ENCHANTMENT HIV Study
Recruiting
Persons with HIV, even those well-treated, are at increased risk for heart disease when compared to the general population. Two hormones called aldosterone and brain natriuretic peptide (BNP), which have been shown to be abnormal in HIV, may be associated with inflammation as well as early changes in structure and function of the heart. This study is being conducted to evaluate whether therapies to block aldosterone and increase BNP levels may reduce the burden and progression of heart failure t... Read More
Gender:
ALL
Ages:
Between 40 years and 70 years
Trial Updated:
12/24/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: HIV/AIDS, Heart Failure With Preserved Ejection Fraction
Intravascular Ultrasound in Patients With End-stage Renal Disease on Dialysis
Recruiting
Hemodialysis represents a life line of patients with end stage renal disease, who are commonly maintained on hemodialysis through catheters. Prolonged exposure to these catheters eventually damages the walls of veins, which results in stenosis at the local site. This condition is called central venous stenosis (CVS) and affects number of patients on hemodialysis in the United States and can compromise the dialysis efficacy. The current diagnostic modality for CVS is venography, which has several... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
12/24/2024
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: End Stage Renal Disease
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
Recruiting
This research study is evaluating a drug called ABL001 taken in combination with dasatinib (Sprycel®) and prednisone (a steroid) as a possible treatment for B-cell Acute Lymphoblastic Leukemia that is BCR-ABL positive (BCR-ABL+ B-ALL) or Chronic Myeloid Leukemia (CML) in lymphoid blast crisis. BCR-ABL+ B-ALL is also called Philadelphia chromosome positive Acute Lymphoblastic Leukemia (Ph+ ALL).
It is expected that 40-65 people will take part in this research study.
* ABL001
* Dasatinib (Spryce... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/23/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +1 locations
Conditions: B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL
A Novel Social Emotional Learning Curriculum for Youth With Epilepsy
Recruiting
Youth with epilepsy (YWE) are significantly more likely than their peers without epilepsy to experience isolation, interpersonal victimization, and low relationship satisfaction. This is a serious health concern. Poor social support, real or perceived, is consistently correlated to worsened outcomes in every domain of health-related quality of life. As YWE are two to five times more likely than their peers without epilepsy to develop a mental health condition, poor social support is likely a bid... Read More
Gender:
ALL
Ages:
Between 12 years and 26 years
Trial Updated:
12/23/2024
Locations: Boston Medical Center, Neurology and remote, Boston, Massachusetts
Conditions: Epilepsy
Multimodal Outcome CHAracterization in Comatose Cardiac Arrest Patients Registry and Tissue Repository
Recruiting
Cardiovascular disease remains the leading cause of death in the United States. Mortality rates of cardiac arrest range from 60-85%, and approximately 80% of survivors are initially comatose. Of those who survive, 50% are left with a permanent neurological disability, and only 10% are able to resume their former lifestyle. Early prognosis of comatose patients after cardiac arrest is critical for management of these patients, yet predicting outcome for these patients remains quite challenging.
T... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/22/2024
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: Cardiac Arrest
Influenza & COVID-19 Obstetric and Perinatal Epidemiology Study in India
Recruiting
This study will be conducted as a prospective cohort study, enrolling all eligible women in their first trimester of pregnancy during a baseline visit during week 6-13 of pregnancy at Government Medical College Hospital, Nagpur. The Hospital provides primary, secondary, and tertiary care and the obstetric department delivers about 10,000 babies a year. The hypothesis is that co-infection of other respiratory viruses (ORV), particularly COVID-19 and Influenza increases the risk of adverse pregnan... Read More
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
12/20/2024
Locations: Boston University School of Public Health, Global Health, Boston, Massachusetts
Conditions: Influenza, COVID-19, SARS-COV-2 Infection, Other Respiratory Viruses, Perinatal Morbidity, Infant Morbidity
Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes
Recruiting
Patients with Type 2 Diabetes Mellitus (T2DM) have changes in blood vessel health that can lead to a higher chance of developing heart attacks or strokes. New medications for T2DM including dapagliflozin, which is a Sodium-Glucose Cotransporter-2 inhibitor (SGLT2) inhibitor, may help protect the heart and blood vessels.
The overarching objective of this mechanistic study is to learn how a Sodium-Glucose Cotransporter-2 (SGT2) inhibitor, dapagliflozin, impacts vascular health in patients with Ty... Read More
Gender:
ALL
Ages:
Between 30 years and 75 years
Trial Updated:
12/20/2024
Locations: BU School of Medicine Evans 748, Boston, Massachusetts
Conditions: Diabetes Mellitus, Type 2, Endothelial Dysfunction
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy
Recruiting
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This study includes 4 periods: Screening, open label, randomized withdrawal, and long-term treatment extension (LTE).
Gender:
ALL
Ages:
30 years and above
Trial Updated:
12/20/2024
Locations: TBPH Investigative Site, Boston, Massachusetts
Conditions: Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer
Recruiting
The investigators will compare the application of two different creams for the treatment of low-risk skin cancers-superficial basal cell carcinoma (sBCC) and squamous cell carcinoma in situ (SCCis). 5-Fluorouracil cream is currently FDA approved for the treatment of superficial basal cell carcinoma and is routinely used by dermatologists across the country and at Boston Medical Center (BMC) for SCCis. The normal treatment regimen is 4 weeks of the 5-fluorouracil cream for both skin cancers.
The... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2024
Locations: Boston Medical Center Dermatology Clinic, Boston, Massachusetts
Conditions: Superficial Basal Cell Carcinoma, Squamous Cell Carcinoma in Situ
The ENCIRCLE Trial
Recruiting
This study will establish the safety and effectiveness of the SAPIEN M3 System in subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available surgical or transcatheter treatment options are deemed unsuitable.
Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Mitral Regurgitation, Mitral Valve Insufficiency
1705 - 1716 of 2672